Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group

BACKGROUND: Sunitinib malate, a targeted tyrosine kinase inhibitor, is standard of care for metastatic renal cell carcinoma (mRCC) and serves as the active comparator in several ongoing mRCC clinical trials. This analysis reports benchmarks for clinical outcomes based on International Metastatic Ren...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Genitourin Cancer
Main Authors: Rini, Brian I, Hutson, Thomas E., Figlin, Robert A., Lechuga, Maria Josè, Valota, Olga, Serfass, Lucile, Rosbrook, Brad, Motzer, Robert J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6690431/
https://ncbi.nlm.nih.gov/pubmed/29853320
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2018.04.005
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados